NeuroScientific Biopharmaceuticals Limited (ASX:NSB)
Australia flag Australia · Delayed Price · Currency is AUD
0.0640
-0.0010 (-1.54%)
Aug 26, 2026, 1:01 PM AEST

ASX:NSB Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Other Revenue
0.63-2.214.95-
0.63-2.214.95-
Revenue Growth
---55.34%416.60%-
Cost of Revenue
0.14-00.020.050.07
Gross Profit
0.4902.194.91-0.07
Selling, General & Admin
2.070.991.361.751.8
Research & Development
1.080.130.494.037.22
Amortization of Goodwill & Intangibles
1.370.090.090.050.05
Operating Expenses
4.962.012.036.0810.44
Operating Income
-4.48-2.010.16-1.17-10.5
Interest Expense
-0-0-0.01-0-
Interest & Investment Income
-0.170.180.110.07
EBT Excluding Unusual Items
-4.48-1.850.32-1.07-10.44
Asset Writedown
-0.21----
Pretax Income
-4.69-1.850.32-1.07-10.44
Net Income
-4.69-1.850.32-1.07-10.44
Net Income to Common
-4.69-1.850.32-1.07-10.44
Net Income Growth
-----
Shares Outstanding (Basic)
338147145143143
Shares Outstanding (Diluted)
338147145143143
Shares Change
130.21%1.49%0.72%--
EPS (Basic)
-0.01-0.010.00-0.01-0.07
EPS (Diluted)
-0.01-0.010.00-0.01-0.07
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Free Cash Flow
-2.78-0.940.04-2.3-6.95
Free Cash Flow Per Share
-0.01-0.01--0.02-0.05
Gross Margin
77.06%-98.90%99.07%-
Operating Margin
-711.56%-7.02%-23.65%-
Profit Margin
-745.66%-14.66%-21.57%-
Free Cash Flow Margin
-441.39%-1.92%-46.52%-
EBITDA
-3.09-1.920.25-1.11-10.44
EBITDA Margin
--11.15%-22.48%-
D&A For EBITDA
1.380.090.090.060.06
EBIT
-4.48-2.010.16-1.17-10.5
EBIT Margin
--7.02%-23.65%-